

# INCLIVA | VLC

Instituto de Investigación Sanitaria

## Organize:

- INCLIVA Biomedical Research Institute.
- ERI Biotecmed, University of Valencia.

## Registration:

- Free registration through the following link:  
<https://goo.gl/forms/TzzRMa7gQmGQt3er2>
- Capacity up to 104 people



## Meeting website:

[http://www.incliva.es/formacion/jornadas/first-spanish-meeting-on-oligonucleotide-therapeutics-\(smot1\)](http://www.incliva.es/formacion/jornadas/first-spanish-meeting-on-oligonucleotide-therapeutics-(smot1))

## INCLIVA | VLC

Biomedical Research Institute



VNIVERSITAT  
D VALÈNCIA



Facultad de  
Ciencias Biológicas

Department of Genetics

# INCLIVA | VLC

Instituto de Investigación Sanitaria



INTEGRANDO TALENTO  
*mejorando tu calidad de vida*

Friday 1st of June, 2018

## First Spanish Meeting on Oligonucleotide Therapeutics (SMOT1)

Conference room Biblioteca Eduard  
Boscá, Universidad de Valencia,  
campus de Burjasot



### MEETING DIRECTOR:

- Dr. Beatriz Llamusi University of Valencia, Department of Genetics

### SESSION I. 09:00 – 11:00 am.

#### “Oligonucleotide synthesis and chemical modifications”

- **“Historical perspective on oligonucleotide synthesis”**. Dr. Ramón Eritja. IQAC, Barcelona.
- **“Tools and techniques to assess quality of therapeutic nucleic acids (TNAs)”**. Dr. Philipp Hadwiger. Axolabs, LGC.
- **“Aptamers against MNK in the treatment of breast cancer”**. Dr. Celia Pinto. IRYCIS-hospital, Madrid.
- **“A lesson learned from a virus: The Viromer® Delivery Technology”**. Dr. Christian Reinsch, Head of Development at Lypocalix.

### SESSION II. 11:30 am -02:00 p.m

#### “Preclinical studies”

- **“Derepressing muscleblind expression by miRNA inhibitors ameliorates Myotonic Dystrophy-like phenotypes”**. Dr. Beatriz Llamusi, University of Valencia.
- **“Peptide enhanced delivery of oligonucleotides to the skeletal muscle and CNS”**. Dr. Suzan Hammond. University of Oxford.
- **“Innovative therapeutic approaches to chronic kidney disease”**. Dr. Laura García, IRYCIS, Madrid.
- **“Cancer treatment using antisense oligonucleotides to regulate splicing”**. Dr. Jordi Hernández, CRG, Barcelona.

### LUNCH BREAK. 02:00 - 03:00 pm

### SESSION III. 03.00 – 05.30 PM

#### “Clinical studies”

- **“Preclinical and clinical studies using oligonucleotide therapies in Duchenne”**. Dr. Virginia Arechavalagomez, Instituto Biocruces, Bilbao.
- **“saRNA technology to increase protein expression”**. Dr. David Blakey, CEO at Mina Therapeutics.
- **“Topical therapies based on siRNA for ocular diseases”**. Dr. Covadonga. I+D manager at Sylentis.
- **“Regulatory advice on oligonucleotide-based therapy regulation”**. Lidia Cánovas. CEO at ASPHALION.
- **“Oligonucleotides in the current therapeutic scenario. Critical analysis”**. Dr. Joaquín Sáez, European correspondent of the European clinical research infrastructure network (ECRIN) in Spain.

### PARTNERSHIPS:

